EC Number   |
Disease |
PubMed ID  |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.22.43 | Myasthenia Gravis |
12925692 |
Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. |
causal interaction
diagnostic usage
unassigned |
3
1
0 |
| 3.4.22.43 | Keratoconus |
15728537 |
Increased levels of catalase and cathepsin V/L2 but decreased TIMP-1 in keratoconus corneas: evidence that oxidative stress plays a role in this disorder. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
2
4
1 |
| 3.4.22.43 | Arthritis |
17869649 |
Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
4
1 |
| 3.4.22.43 | Arthritis, Juvenile |
17869649 |
Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
4
1 |
| 3.4.22.43 | Arthritis, Rheumatoid |
17869649 |
Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
4
1 |
| 3.4.22.43 | Autoimmune Diseases |
17869649 |
Polymorphisms in the cathepsin L2 (CTSL2) gene show association with type 1 diabetes and early-onset myasthenia gravis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
4
1 |
| 3.4.22.43 | Alopecia |
17934903 |
Evaluation of the CTSL2 Gene as a Candidate Gene For Alopecia X in Pomeranians and Keeshonden. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
1
2
1 |
| 3.4.22.43 | Dermatitis, Atopic |
19438477 |
The cystatin M / E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
3
4
1
0 |
| 3.4.22.43 | Psoriasis |
19438477 |
The cystatin M / E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
3
4
1
0 |
| 3.4.22.43 | Atherosclerosis |
20578711 |
Solution phase synthesis of a combinatorial library of chalcones and flavones as potent cathepsin V inhibitors. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
